Acadian Asset Management LLC Invests $37,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 864 shares of the biopharmaceutical company’s stock, valued at approximately $37,000.

Other institutional investors also recently bought and sold shares of the company. Farallon Capital Management LLC raised its stake in shares of Agios Pharmaceuticals by 34.1% in the first quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock worth $163,469,000 after purchasing an additional 1,423,000 shares during the last quarter. Vanguard Group Inc. raised its position in Agios Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after buying an additional 44,583 shares during the last quarter. Armistice Capital LLC lifted its stake in Agios Pharmaceuticals by 6.0% during the 4th quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company’s stock valued at $78,479,000 after acquiring an additional 200,000 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Agios Pharmaceuticals by 5.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company’s stock valued at $57,832,000 after acquiring an additional 137,873 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after acquiring an additional 388,381 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently issued reports on AGIO shares. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday. The Goldman Sachs Group boosted their price objective on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a report on Tuesday, June 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $51.33.

Insider Buying and Selling

In other news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.93% of the stock is owned by insiders.

Agios Pharmaceuticals Stock Down 1.8 %

NASDAQ:AGIO opened at $46.55 on Friday. Agios Pharmaceuticals, Inc. has a 52 week low of $19.80 and a 52 week high of $50.35. The stock’s 50-day moving average price is $45.71 and its 200-day moving average price is $39.19. The stock has a market capitalization of $2.64 billion, a PE ratio of -7.37 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The business had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The firm’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same period in the previous year, the business posted ($1.51) earnings per share. Sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -4.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.